Feasibility and safety of general anesthesia for bronchial thermoplasty: a description of early 10 treatments

Abstract

Bronchial thermoplasty (BT) is a recently introduced bronchoscopic treatment for patients with asthma refractory to pharmacotherapy. Intraprocedural sedation management is important for successful performance of BT. However, the results of general anesthesia in patients undergoing BT have not been well described. The aim of this study was to evaluate the feasibility and safety of general anesthesia in patients undergoing BT. We retrospectively reviewed the records of 10 consecutive BT treatments performed under general anesthesia in 4 patients. The feasibility outcomes were coughing and body movement during the procedure, procedure abandonment, and the relative frequency of thermal activation failure. The safety outcomes were bronchospasm and hypoxemia during the procedure, respiratory symptoms, and the need for oxygen after the procedure. Coughing occurred in two treatments. Neither body movement nor procedure abandonment occurred in any treatments. Neither intraprocedural bronchospasm nor hypoxemia occurred in any treatments. Respiratory symptoms occurred in 7 of 10 treatments within 1 day after the procedure and resolved within 4 days, which is comparable with a previous report. These results indicate that general anesthesia is feasible and safe for patients undergoing BT.

http://ift.tt/2DJNLQc

Cancers, Vol. 10, Pages 81: Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors

Cancers, Vol. 10, Pages 81: Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors

Cancers doi: 10.3390/cancers10030081

Authors: Jeffrey Holden Christian Cunningham

The Hippo pathway is a critical transcriptional signaling pathway that regulates cell growth, proliferation and organ development. The transcriptional enhanced associate domain (TEAD) protein family consists of four paralogous transcription factors that function to modulate gene expression in response to the Hippo signaling pathway. Transcriptional activation of these proteins occurs upon binding to the co-activator YAP/TAZ whose entry into the nucleus is regulated by Lats1/2 kinase. In recent years, it has become apparent that the dysregulation and/or overexpression of Hippo pathway effectors is implicated in a wide range of cancers, including prostate, gastric and liver cancer. A large body of work has been dedicated to understanding the therapeutic potential of modulating the phosphorylation and localization of YAP/TAZ. However, YAP/TAZ are considered to be natively unfolded and may be intractable as drug targets. Therefore, TEAD proteins present themselves as an excellent therapeutic target for intervention of the Hippo pathway. This review summarizes the functional role of TEAD proteins in cancer and assesses the therapeutic potential of antagonizing TEAD function in vivo.

from Cancer via ola Kala on Inoreader http://ift.tt/2GJ13PV
via IFTTT

Cancers, Vol. 10, Pages 81: Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors

Cancers, Vol. 10, Pages 81: Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors

Cancers doi: 10.3390/cancers10030081

Authors: Jeffrey Holden Christian Cunningham

The Hippo pathway is a critical transcriptional signaling pathway that regulates cell growth, proliferation and organ development. The transcriptional enhanced associate domain (TEAD) protein family consists of four paralogous transcription factors that function to modulate gene expression in response to the Hippo signaling pathway. Transcriptional activation of these proteins occurs upon binding to the co-activator YAP/TAZ whose entry into the nucleus is regulated by Lats1/2 kinase. In recent years, it has become apparent that the dysregulation and/or overexpression of Hippo pathway effectors is implicated in a wide range of cancers, including prostate, gastric and liver cancer. A large body of work has been dedicated to understanding the therapeutic potential of modulating the phosphorylation and localization of YAP/TAZ. However, YAP/TAZ are considered to be natively unfolded and may be intractable as drug targets. Therefore, TEAD proteins present themselves as an excellent therapeutic target for intervention of the Hippo pathway. This review summarizes the functional role of TEAD proteins in cancer and assesses the therapeutic potential of antagonizing TEAD function in vivo.

http://ift.tt/2GJ13PV

Letters about Published Papers: Letters of comment about recently published papers should be sent by email to: bgoldspiel@verizon.net

Journal of Oncology Pharmacy Practice, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2ppSB0B
via IFTTT

Prolonged voriconazole treatment in a patient with chronic lymphocytic leukemia resulting in a litany of chronic overlapping toxicities

Journal of Oncology Pharmacy Practice, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2DGUPg7
via IFTTT

Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study

Journal of Oncology Pharmacy Practice, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2ppweYZ
via IFTTT

Primary mucinous carcinoma of thyroid gland with prominent signet-ring-cell differentiation: a case report and review of the literature

http://ift.tt/2FNrWF7